Hewlett Packard Enterprise Co vs Neurocrine Biosciences Inc — how do they compare? Hewlett Packard Enterprise Co trades at $56.13 (market cap $72.01B), while Neurocrine Biosciences Inc trades at $158.08 (market cap $16.46B). The key difference: Hewlett Packard Enterprise Co is far larger — about 4.4× Neurocrine Biosciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| HPE | NBIX | |
|---|---|---|
Market Cap | $72.01B | $16.46B |
Sector | Technology | Health |
52-Week High | $56.14 | $185.50 |
52-Week Low | $20.01 | $123.10 |
Enterprise Value | $87.96B | $16.48B |
Dividend Yield | 1.05% | — |
Signals from Pluang's Aura AI — not financial advice
HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.
The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →